Viking Therapeutics released updated data from an obesity drug trial showing that most participants kept their weight down after moving from a weekly injection to a less frequent dosing schedule. The company did not disclose full numerical details in the report, but the market response was immediate: Viking's shares surged on the news.
According to BioPharma Dive, one analyst interpreted the results as a potential boost to Viking's competitive positioning. The ability to maintain weight loss with fewer injections could differentiate the drug in a crowded obesity treatment field, where dosing convenience is a major factor for patients and prescribers.
The findings are based on a single source and have not been independently verified. Longer-term durability and safety data would be needed to confirm whether the maintenance effect holds beyond the trial period.